Detail akcie Illumina Inc online

Business Summary: Illumina, Inc. is engaged in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Its products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. Its product categories include Instruments, Kits & Reagents, Selection Tools, and Software & Analysis. Its Instruments category include sequencing platforms, microarray scanners, and IVD instruments. Its Kits & Reagents category consists of library preparation kits, sequencing reagents, microarray kits, clinical research products, and IVD products. Its Selection Tools category include Library Prep & Array Kit Selector, Gene Panel & Array Finder, DesignStudio Custom Assay Designer, and other. Its services include sequencing services, microarray services, proactive instrument monitoring, and instrument services and training. It is also a developer of an emerging and highly differentiated single-cell technology.
Financial Summary: BRIEF: For the nine months ended 29 September 2024, Illumina Inc revenues decreased 3% to $3.27B. Net loss increased 43% to $1.41B. Revenues reflect GRAIL segment decrease of 11% to $56M, Greater China segment decrease of 25% to $228M, Americas segment decrease of 3% to $1.85B, Asia, Middle East, and Africa segment decrease of 2% to $329M. Higher net loss reflects GRAIL segment loss increase of 62% to $2.31B.